Paxman AB (FRA:B0F) 5-Year EBITDA Growth Rate: 0.00% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:B0F Paxman AB FRA:B0F
82 GF Score
Price €5.09
GF Value €5.63
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Paxman AB 5-Year EBITDA Growth Rate?

Paxman AB FRA:B0F +0.99% 82 5-Year EBITDA Growth Rate is 0.00% as of Jun. 2026. GuruFocus rates FRA:B0F with a GF Score™ of 82/100 and a GF Value™ of €5.63 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Paxman AB's EBITDA per Share for the three months ended in Jun. 2026 was €0.05.

During the past 12 months, Paxman AB's average EBITDA Per Share Growth Rate was -30.00% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 14.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 9 years, the highest 3-Year average EBITDA Per Share Growth Rate of Paxman AB was 165.40% per year. The lowest was 14.50% per year. And the median was 35.80% per year.

Paxman AB  (FRA:B0F) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Paxman AB 5-Year EBITDA Growth Rate Related Terms

FRA:B0F vs ABT, SYK, MDT: 5-Year EBITDA Growth Rate Comparison

For the Medical Devices subindustry, Paxman AB's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Paxman AB 5-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Paxman AB's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Paxman AB's 5-Year EBITDA Growth Rate falls into.


FRA:B0F
82GF Score
Paxman AB FRA:B0F
5-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Paxman AB 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 5-Year EBITDA Growth Rate of 0.00% mean?
Paxman AB (FRA:B0F) has a 5-Year EBITDA Growth Rate of 0.00% as of Jun. 2026. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Paxman AB and its competitors.
Is Paxman AB's 5-Year EBITDA Growth Rate too high?
Paxman AB's current 5-Year EBITDA Growth Rate is 0.00%. Overall, Paxman AB has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Paxman AB's 5-Year EBITDA Growth Rate compare to ABT and SYK?
Paxman AB's 5-Year EBITDA Growth Rate of 0.00% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
A good 5-Year EBITDA Growth Rate depends on the Medical Devices & Instruments industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Paxman AB and its competitors. Paxman AB's current 5-Year EBITDA Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Paxman AB stock overvalued right now?
Based on GuruFocus' analysis, Paxman AB (FRA:B0F) is currently considered Modestly Undervalued. The stock's GF Value™ is €5.63, compared to a current price of €5.09 — trading 9.6% below its estimated fair value. The current 5-Year EBITDA Growth Rate is 0.00%. Paxman AB's overall GF Score™ is 82/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For Paxman AB (FRA:B0F), the current 5-Year EBITDA Growth Rate is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Paxman AB (FRA:B0F) Overvalued in 2026?

Based on GuruFocus' analysis, Paxman AB stock appears to be undervalued. The current stock price of €5.09 is trading 9.6% below its estimated GF Value™ of €5.63. GuruFocus considers Paxman AB to be Modestly Undervalued.

Key valuation signals for FRA:B0F:

  • 5-Year EBITDA Growth Rate: 0.00%
  • GF Value™: €5.63 vs. price of €5.09 (9.6% below fair value)
  • GF Score™: 82/100 with 2 warning signs

No single metric tells the full story. See the FRA:B0F stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Paxman AB Business Description

Other Exchanges PAX:Sweden
Address Pirgatan 13, Karlshamn, SWE, SE-374 35
Paxman AB is a Sweden-based company engaged in the development of the PAXMAN Scalp Cooling System, which has been developed by the Paxman family to reduce hair loss in breast cancer patients undergoing chemotherapy. The portfolio includes both the Paxman and Digni Capsystems with several installations in hospitals, clinics, and treatment centres world-wide.
82GF Score

Get the complete analysis for FRA:B0F

5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.09
Price
€5.63
GF Value